Funding for this research was provided by:
Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan province open project (HYX20003)
Chengdu Gaoxin Medical Association 2020 Annual Cancer Intervention Special Research Fund (2020S02)
National Natural Science Foundation of China (81925019, 81422023, 82003147, 81603015, 81871404, 82003147 and U1705281)
Major State Basic Research Development Program of China (2017YFA0205201)
Fundamental Research Funds for the Central Universities (20720190088, 20720200019)
Received: 22 April 2022
Accepted: 18 May 2022
First Online: 3 June 2022
: All procedures involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the Institutional Review Board of Affiliated Hospital of North Sichuan Medical College (IRB No. 2022ER146-1) and registered at chictr.org.cn (ID: ChiCTR2200058803). The subjects signed and gave the written informed consent.
: All authors agree to be published.
: The authors declare that they have no competing interests.